- Oops!Something went wrong.Please try again later.
Nedosiran demonstrated safety and tolerability results consistent with previously reported studies.
Patients administered nedosiran also showed a trend in urinary oxalate (Uox) reduction; however, these reductions did not meet prespecified secondary efficacy endpoint criteria.
Dicerna plans to submit an FDA marketing application for nedosiran to treat PH1 in Q4 of 2021.
No subjects in either group achieved the prespecified secondary efficacy endpoint, a greater than 30% decrease from baseline in 24-hour Uox excretion on at least two consecutive visits over the three-month observation period.
However, all patients administered a single dose of nedosiran demonstrated Uox reductions relative to baseline at one or more time points during the three months.
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.
Price Action: DRNA shares are up 1.73% at $21.15 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.